The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
Open accessAbstract
Purpose: Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes. Patients and Methods: In a cohort study, patients with metastasized neuroendocrine cancer were treated with repeated cycles of 90 yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([90 Y-DOTA]-TOC) or with cycles alternating between [90 Y-DOTA]-TOC and 177 lutetium-labeled DOTA-TOC ([177 Lu-DOTA]-TOC) until tumor progression or permanent toxicity. Multivariable Cox regression and competing risk regression were used to study predictors of survival and renal toxicity in patients completing three or more treatment cycles. Results: A total of 486 patients completed three or more treatment cycles; 237 patients received [90 Y-DOTA]-TOC and 249 patients received [90 Y-DOTA]-TOC + [177 Lu-DOTA]-TOC. Patients receiving [90 Y-DOTA]-TOC + [177 Lu-DOTA]-TOC had a significantly longer survival than patients receiving [90 Y-DOTA]-TOC alone (5.51 v 3.96 years; hazard ratio, 0.64; 95% CI, 0.47 to 0.88; P = .006). The rates of severe hematologic toxicities (6.3% v 4.4%; P = .25) and severe renal toxicity (8.9% v 11.2%; P = .47) were comparable in both groups. Conclusion: [90 Y-DOTA]-TOC + [177 Lu-DOTA]-TOC was associated with improved overall survival compared with [90 Y-DOTA]-TOC alone in patients completing three or more cycles of treatment. Contrary to the current practice in radiopeptide therapy, our results suggest an advantage of using a combination of radioisotopes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Cited by
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Recommendations for management of patients with neuroendocrine liver metastases
Frilling, A., Modlin, I. M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Lau, W.-Y., Klersy, C., Vilgrain, V., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70362-0 · Cited by 527
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Metadata
- Authors
- Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K. T., Mäcke, H. R., Müller-Brand, J., Rochlitz, C., Briel, M., & Walter, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-04-01
- Volume
- 30
- Issue
- 10
- Pages
- 1100-1106
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148881212
- Cited by
- 189
- References
- 2
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers. https://app.cochat.ai/papers/10.1200/jco.2011.37.2151
- The paper
- Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K. T., Mäcke, H. R., Müller-Brand, J., Rochlitz, C., Briel, M., & Walter, M. A. (2012). Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.37.2151
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.